ArticleDiagnostic pathology2026
Intrapulmonary solitary fibrous tumor: clinicopathological analysis of 29 cases with emphasis on morphological spectrum and immunohistochemical profile.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrapulmonary solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can mimic pulmonary adenofibroma (PAF) when respiratory epithelium is entrapped.
methodsWe retrospectively analyzed 29 intrapulmonary SFTs, reviewing clinical, histopathological, and immunohistochemical features. STAT6, CD34, ER, and PR were evaluated.
resultsThe cohort included 18 males and 11 females (mean age 55.3 years); 69.0% were asymptomatic. Mean tumor size was 4.11 cm, with pleural attachment in 62.1%. Histologically, 79.3% showed biphasic cellularity, 86.2% had staghorn vessels, and 44.8% exhibited entrapped epithelium. Stromal changes included collagenization (89.7%), hemorrhage (24.1%), myxoid change (20.7%), cystic change (6.9%), and multinucleated giant cells (3.4%). Risk stratification identified 25 low-risk, three intermediate-risk, and one high-risk case. STAT6 was positive in all tested cases (28/28, 100%), and CD34 in 96.3%. Among 22 evaluable cases, 19 (86.4%) showed ER < PR. During a mean follow-up of 36.7 months, one high-risk patient (3.4%) developed local recurrence.
conclusionIntrapulmonary SFT has a broad morphological spectrum with frequent epithelial entrapment as a key diagnostic pitfall. STAT6 is a reliable diagnostic marker, while ER < PR is common but of uncertain significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.